<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667790/" ref="ordinalpos=4852&amp;ncbi_uid=4966021&amp;link_uid=PMC3667790" image-link="/pmc/articles/PMC3667790/figure/pone-0064088-g007/" class="imagepopup">Figure 7. Hypothetical model illustrating the DSG3-plakoglobin <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> modulating cell carcinogenesis in head and neck cancer..  From: DSG3 Facilitates Cancer Cell Growth and Invasion through the DSG3-Plakoglobin-TCF/LEF-Myc/Cyclin D1/MMP <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span>. </a></div><br /><div class="p4l_captionBody">(A) In cancer cells, DSG3 is overexpressed and captures more molecules of plakoglobins in the membrane. Loss of the antagonist function of plakoglobin results in more molecules of β-catenin entering the nucleus, which subsequently activates the expression of TCF/LEF downstream target genes c-myc, cyclin D1, and MMP-7 resulting in malignant cells. (B) Silencing DSG3 by shRNA treatment reverses the effects of DSG3, resulting in translocation of plakoglobin to the nucleus thus rendering the negative regulatory effect of plakoglobin on TCF/LEF transcription. (Pg: plakoglobin; B: β-catenin).</div></div>